A randomized, double-blind phase 3 trial compared pembrolizumab plus ipilimumab to pembrolizumab alone in treatment-naïve metastatic NSCLC patients with PD-L1 Tumor Proportion Score ≥50% and no EGFR or ALK alterations. This evidence concerns the gene CD274 and neoplasm.